Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031458 | 0.94 | F10 (0.75) | F10 | |
| SCHEMBL4031464 | 0.94 | F10 (0.75) | F10 | |
| SCHEMBL5625141 | 0.92 | F10 (0.73) | F10ABCB11F2ST14 | |
| SCHEMBL5628214 | 0.92 | F10 (0.73) | F10ABCB11F2ST14 | |
| SCHEMBL5625381 | 0.90 | F10 (0.73) | F10ABCB11F2ST14 | |
| SCHEMBL5625917 | 0.90 | F10 (0.71) | F10ABCB11F2ST14 | |
| SCHEMBL5630405 | 0.90 | F10 (0.71) | F10ABCB11F2ST14 | |
| SCHEMBL5627627 | 0.90 | F10 (0.73) | F10ABCB11F2ST14 | |
| SCHEMBL5629786 | 0.89 | F10 (0.55) | F10ABCB11F2ST14 | |
| SCHEMBL4035888 | 0.88 | F10 (0.75) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | claimed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | F10 9/4885ABCB11 838/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.